海南海藥(000566.SZ)半年度預虧1400-2000萬元、同比大幅收窄
格隆匯7月8日丨海南海藥(000566.SZ)公佈,預計2022年半年度歸屬於上市公司股東的淨虧損1400-2000萬元,上年同期為虧損37712.93萬元;扣除非經常性損益後的淨虧損4200萬元-6200萬元,上年同期為虧損21729.4萬元。
虧損金額較上年同期有較大幅度下降。公司生產經營呈現良好態勢,2022年第二季度單季度實現扭虧為盈。主要原因如下:
1.公允價值變動損益同比上升。2022年上半年公允價值變動損益預計金額約-75萬元,較上年同期增加1.99億元。主要系本報吿期公司處置部分股票導致交易性金融資產減少,交易性金融資產的公允價值變動對損益的影響較上年同期減少所致。
資產處置收益同比上升。2022年上半年資產處置收益預計金額約1900萬元,較上年同期-72萬元增加約2000萬元。主要系公司優化資產結構,積極盤活、處置低效資產所致。
上述事項均屬於非經常性損益。
2.管理費用同比下降。2022年上半年管理費用預計金額約0.8億元,較上年同期1.47億元減少約0.67億元。主要系本報吿期公司開展提質增效,降本控費取得成效;子公司鹽城開元醫藥化工有限公司、江蘇漢闊生物有限公司全面復產,停工損失較上年同期減少所致。
3.財務費用同比下降。2022年上半年財務費用預計金額約0.79億元,較上年同期0.99億元減少約0.2億元。主要系公司優化融資結構,融資費用較上年同期減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.